血液检查确诊阿兹海默症初现曙光 分享到
Possible Blood Test for Alzheimer’s Shows Early Promise 2018-02-1233212

中英
Việt-Anh
ไทย-อังกฤษ
英文

双击原文单词查看解释

原文跟读

Researchers in Japan and Australia say they have made progress in developing a blood test that could one day help doctors identify who might get Alzheimer’s disease.
日本和澳大利亚的研究人员表示他们在一项血液检测上取得进展,该项检测未来可以帮助医生判断或许会患阿兹海默症的病人。
The scientists said the test can recognize a protein known as amyloid beta, which other studies have linked to Alzheimer’s.They said it was correct more than 90 percent of the time in a study involving over 370 people.
科学家们表示,该血液检测可以识别一种名叫乙型淀粉样蛋白的蛋白质,其他研究证明该蛋白与阿兹海默症有联系。科学家们表示在涉及370多人的调查中,该结果的正确率超过百分之九十。
The findings were published in the journal Nature.
该调查结果发布在《自然》杂志上。
Alzheimer’s disease is the most common form of dementia.Experts believe dementia affects close to 50-million people worldwide. By the year 2050, it is expected to affect more than 131 million people. Those numbers come from Alzheimer’s Disease International, a non-profit group.
阿兹海默症是一种常见的痴呆症。专家认为痴呆会影响全世界近五千万人。截止至2050年,痴呆预计会影响超过1.31亿人。这一数字来自一家非盈利组织,国际失智症协会。
Currently, doctors have two ways to identify a buildup of amyloid beta in the brain. One is a brain scan or brain imaging; the other is invasive cerebrospinal fluid testing, also known as a spinal tap.But both tests are invasive, costly and may only show results when the disease has already started to progress.
目前,医生有两种方式确定大脑中乙型淀粉样蛋白的发展。一种是脑部扫描或者叫脑成像,另一种是侵入性脑脊液检测,又名脊椎抽液。两种检测方式都具有侵入性,成本高,而且只有当疾病已经开始发展时才能检测出结果。
There is no treatment that can slow the progression of Alzheimer’s. Current drugs can only ease some of the effects of the disease.
目前没有治疗方法可以延缓阿兹海默症的发展。现有的药物只能缓解该疾病的部分症状。
Having a simple, low-cost blood test could make it easier for drug companies to find enough people who are at risk of developing Alzheimer’s to test new medicines, said Katsuhiko Yanagisawa. He was one of the leaders of the study. He works at the Japanese National Center for Geriatrics and Gerontology.
简单低成本地进行血液检测能够让制药公司更容易地发掘足够多的有患阿兹海默症风险的人来试用新药物,胜彦柳泽表示。他是该研究的领导者之一。他就职于日本老年病学和老年医学中心。
Alzheimer’s disease is thought to start developing years before patients have any signs of memory loss. Experts say an important factor in finding an effective treatment will be the ability to recognize signs of the disease early.
据认为阿兹海默症在病人显示出失忆的症状前就已经开始发展数年之久了。专家们表示找到有效治疗的方法最重要的一个因素就是及早发现该疾病的征兆。
You have got to walk before you run, said Colin Masters, a co-leader of the study and a professor at the University of Melbourne in Australia.
“在你跑步之前你得先走,”科林·马斯特斯说道,他是澳大利亚墨尔本大学的教授,也是该项研究的另一领导者。
You have to learn to diagnose the disease directly before you can hope to see the effect of therapeutic intervention.And that’s where the real value in this test will come, Masters added.
马斯特斯表示:“在你希望看到治疗干预的结果前,你得先学会直接诊断疾病。这就是这种血液检测的真正价值所在。”
The study involved 252 Australian and 121 Japanese patients.They were all between 60 and 90 years old.
该项研究涉及了252名澳大利亚患者及121名日本患者。年龄都在60岁到90岁。
Scientists not directly involved in the study said it made an important step, but now the findings need to be confirmed.
未直接参与这项研究的科学家们表示该研究迈出了重要的一部,但如今该研究结果还需证实。
Mark Dallas is a teacher at Britain’s University of Reading. He said, "if (it) can be repeated in a larger number of people, this test will give us an insight into changes occurring in the brain that relate to Alzheimer’s disease."
马克·达拉斯是英国雷丁大学的一名教师。他说:“如果该结果能在大量人身上得到反复验证,那么这项检测能够让我们了解到和阿兹海默症相关的大脑中的变化。”
Abdul Hye works at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience. He said the blood test was still a long way from being able to be used in medical centers.
阿卜杜勒·海耶就职于伦敦国王学院的精神病学、心理学和神经科学研究所。他表示血液检测还需经历很长时间才能实际用于医学中心。
John Hardy is a professor of neuroscience at University College London. He said it was a "hopeful study," one that could improve diagnostic accuracy.
约翰·哈迪是英国伦敦大学学院的一名神经系统科学教授。他说这是一项“有希望的研究”,该研究能够提高诊断的准确性。
I’m Bryan Lynn.
布莱恩·林恩为您报道。

点击加载更多

我的生词本